Más

Panjiva_research_logo

Aurobindo shows not all healthcare has been healthy during the pandemic

Coronavirus 501 Earnings 647 Health Care 340 India 463 Quote Watch 417 U.S. 5149

Generic drug manufacturer Aurobindo reported a 2.5% dip in FQ4’21 (to March 31) revenues as a result of lower formulated drug sales in the U.S. That is partly “due to a reduction in hospital procedures on the back of COVID-19” though requests for sales rep visits to doctor surgeries in the U.S. “have improved, but it has not reached the pre-COVID level.” The firm’s supply chain activity already shows it anticipating the recovery, with total Indian exports linked to the firm up by 5.7% year over year in Q1’21. U.S. seaborne imports linked to the firm meanwhile jumped 34.4% year over year ...

Copyright © 2021 Panjiva Supply Chain Intelligence, a product offering from S&P Global Market Intelligence Inc. All rights reserved.